Catheter Ablation versus Standard Conventional Treatment in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE‐AF) ‐ Study Design
- 17 July 2009
- journal article
- research article
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 32 (8), 987-994
- https://doi.org/10.1111/j.1540-8159.2009.02428.x
Abstract
Electrical isolation of the pulmonary veins by catheter ablation is an emerging treatment modality for the treatment of atrial fibrillation (AF) and is increasingly used in patients with heart failure. The catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation trial (CASTLE-AF) is a randomized evaluation of ablative treatment of atrial fibrillation in patients with left ventricular dysfunction. The primary endpoint is the composite of all-cause mortality or worsening of heart failure requiring unplanned hospitalization using a time to first event analysis. Secondary endpoints are all-cause mortality, cardiovascular mortality, cerebrovascular accidents, worsening of heart failure requiring unplanned hospitalization, unplanned hospitalization due to cardiovascular reason, all-cause hospitalization, quality of life, number of therapies (shock and antitachycardia pacing) delivered by the implantable cardioverter-defibrillator (ICD), time to first ICD therapy, number of device-detected ventricular tachycardia and ventricular fibrillation episodes, AF burden, AF free interval, left ventricular function, exercise tolerance, and percentage of right ventricular pacing. CASTLE-AF will randomize 420 patients for a minimum of 3 years at 48 sites in the United States, Europe, Australia, and South America.Keywords
This publication has 25 references indexed in Scilit:
- HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-UpA report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and Approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society.EP Europace, 2007
- Pulmonary Vein Vestibule Ablation for the Control of Atrial Fibrillation in Patients with Impaired Left Ventricular FunctionPacing and Clinical Electrophysiology, 2006
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive SummaryCirculation, 2006
- Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) StudyCirculation, 2004
- Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drugJournal of the American College of Cardiology, 2003
- A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial FibrillationThe New England Journal of Medicine, 2002
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial FibrillationThe New England Journal of Medicine, 2002
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionThe New England Journal of Medicine, 1999
- Long-Term Efficacy of Amiodarone for the Maintenance of Normal Sinus Rhythm in Patients With Refractory Atrial Fibrillation or FlutterThe American Journal of Cardiology, 1995